SCHEMBL200992

SCHEMBL200992

CCCc1ccc(-c2ccc(C(=O)NC(CCS(C)(=O)=O)C(=O)NO)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.51
TAS1R1 Q7RTX1 2/20 0.51
PLK1 P53350 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 2/20 0.44
CTDSP1 Q9GZU7 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CTSS P25774 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTPN1 P18031 1/20 0.40
TSHR P16473 1/20 0.40
MMP2 P08253 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2692848 1.00 TAS1R3 (0.51) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL202853 0.89 TAS1R3 (0.52) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL2692891 0.89 TAS1R3 (0.52) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL201383 0.88 CA2 (0.52) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL200816 0.86 TAS1R3 (0.63) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL404117 0.84 TAS1R3 (0.56) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL203576 0.84 L3MBTL1 (0.56) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL203577 0.84 L3MBTL1 (0.56) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL201342 0.83 TAS1R3 (0.55) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL401475 0.83 TAS1R3 (0.55) TAS1R3TAS1R1PLK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 TAS1R3 1250/4885TAS1R1 1011/4885PLK1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.